Skip to main content
AAN.com

Abstract

Paraneoplastic sensory neuropathy (PSN) usually runs a subacute progressive course, leaving the patient with severe sensory dysfunction in weeks to months. We describe five patients with PSN, high titers of anti-Hu antibodies (type 1 antineuronal nuclear autoantibodies), and an indolent clinical course. The patients had a median age of 55 years (range, 41 to 72). Four had small-cell (3) or undifferentiated large-cell (1) lung cancer. Patients presented with mild, asymmetric sensory symptoms; in two, the neuropathy was predominant in the arms. Two patients also had a visceral neuropathy causing gastrointestinal dysfunction. The PSN was stable or progressed very slowly without treatment for a median of 18 months (range, 5 to 32) and remained so after treatment with immunoglobulins (1 patient), chemotherapy (3), or both therapies (1). All patients were ambulatory, leading an independent life up until the time of the last visit or until death from the tumor (2 patients). The median follow-up was 36 months (range, 22 to 52). A paraneoplastic origin should be considered in patients with mild, very slowly progressive sensory neuropathies.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 44Number 12December 1994
Pages: 2258
PubMed: 7991109

Publication History

Published online: December 1, 1994
Published in print: December 1994

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

F. Graus, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.
I. Bonaventura, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.
M. Uchuya, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.
J. Valls-Solé, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.
R. Reñé, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.
J. M. Leger, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.
E. Tolosa, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.
J. Y. Delattre, MD
Service of Neurology of the Hospital Clinic i Provincial (Drs. Graus, Valls-Solé, and Tolosa), Barcelona; Hospital Mutua de Terrassa (Dr. Bonaventura), Terrassa; C.S. “Príncipes España” (Dr. Reñé), Hospitalet de Llobregat, Spain; and Hôpital Salpêtrière (INSERM U134) (Drs. Uchuya, Leger, and Delattre), Paris, France.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Inflammatory sensory neuronopathies, Revue Neurologique, (2024).https://doi.org/10.1016/j.neurol.2023.12.012
    Crossref
  2. Clinical approach to diagnosis of paraneoplastic neurologic syndromes, Paraneoplastic Neurologic Disorders, (79-96), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00007-4
    Crossref
  3. Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis, Brain Communications, 5, 5, (2023).https://doi.org/10.1093/braincomms/fcad247
    Crossref
  4. Update on Paraneoplastic Neuromuscular Disorders, Current Treatment Options in Neurology, 24, 7, (267-284), (2022).https://doi.org/10.1007/s11940-022-00722-7
    Crossref
  5. Approach to chemotherapy-induced peripheral neuropathy, Neuro-Oncology for the Clinical Neurologist, (356-370), (2021).https://doi.org/10.1016/B978-0-323-69494-0.00028-2
    Crossref
  6. Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review, Journal of Neurology, 269, 3, (1182-1194), (2021).https://doi.org/10.1007/s00415-021-10577-8
    Crossref
  7. Paraneoplastic Neurologic Syndromes, Abeloff's Clinical Oncology, (676-687.e5), (2020).https://doi.org/10.1016/B978-0-323-47674-4.00044-X
    Crossref
  8. Paraneoplastic peripheral neuropathies, Dysimmune Neuropathies, (177-197), (2020).https://doi.org/10.1016/B978-0-12-814572-2.00008-X
    Crossref
  9. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles, Lung Cancer, 111, (150-163), (2017).https://doi.org/10.1016/j.lungcan.2017.07.025
    Crossref
  10. Neurological Complications of Lung Cancer, Cancer Neurology in Clinical Practice, (417-434), (2017).https://doi.org/10.1007/978-3-319-57901-6_22
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share